Functional pleiotropy of organic anion transporting polypeptide OATP2B1 due to multiple binding sites.
The purpose of this study was to examine whether the presence of multiple binding sites can explain the pleiotropy of substrate recognition by OATP2B1, using Xenopus oocytes expressing OATP2B1. OATP2B1-mediated uptake of estrone-3-sulfate apparently exhibited biphasic saturation kinetics, with Km values of 0.10 ± 0.05 and 29.9 ± 12.1 µM and Vmax values of 14.1 ± 6.4 and 995 ± 273 fmol/min/oocyte for high- and low-affinity sites, respectively. Contribution analysis revealed that transport of estrone-3-sulfate mediated by high- and low-affinity sites on OATP2B1 could be evaluated at the concentrations of 0.005 and 50 µM, respectively. pH-dependence study of OATP2B1-mediated estrone-3-sulfate uptake suggested that high- and low-affinity sites show different pH sensitivity. When the inhibitory effect of 12 compounds on estrone-3-sulfate uptake by high- and low-affinity sites on OATP2B1 was examined, 4 compounds appeared to be inhibitors of the high-affinity site on OATP2B1. Two other compounds appeared to be inhibitors for the low-affinity site and four others were inhibitory at both sites. These results indicated the presence of multiple binding sites on OATP2B1 with different affinity for drugs. Accordingly, it is likely that drug-drug and drug-beverage interactions occur only when two drugs share the same binding site on OATP2B1.
Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Yoshiyuki
Y
Shirasaka
Takanori
T
Mori
Megumi
M
Shichiri
Takeo
T
Nakanishi
Ikumi
I
Tamai
D000818:Animals; D001665:Binding Sites; D001692:Biological Transport / Q000187:drug effects; D002478:Cells, Cultured; D004970:Estrone / Q000031:analogs & derivatives / Q000378:metabolism; D005260:Female; D047309:Flavones / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008024:Ligands; D049990:Membrane Transport Modulators / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D009994:Osmolar Concentration; D004364:Pharmaceutical Preparations / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D013256:Steroids / Q000378:metabolism; D014982:Xenopus laevis
D047309:Flavones; D008024:Ligands; D049990:Membrane Transport Modulators; D027361:Organic Anion Transporters; D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins; C450859:SLCO2B1 protein, human; D013256:Steroids; D004970:Estrone; C017296:estrone sulfate